Paragon CareASX:PGC +22.22%56 Altman Z-Score is 3.17 as of Jul. 01, 2026, which is 74% above its 10-year median of 1.82. GuruFocus rates ASX:PGC with a GF Score™ of 56/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 117 Medical Distribution companies, Paragon Care ranks better than 66.67% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.16 is strong.
Paragon Care has a Altman Z-Score of 3.17, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Paragon Care's Altman Z-Score or its related term are showing as below:
ASX:PGC'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.14 Med: 1.82 Max: 3.42
Current: 3.16
During the past 13 years, Paragon Care's highest Altman Z-Score was 3.42. The lowest was -0.14. And the median was 1.82.
Paragon Care (ASX:PGC) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Paragon Care Altman Z-Score Related Terms
Paragon Care Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Paragon Care's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PGC vs MCK, CAH, COR: Altman Z-Score Comparison
For the Medical Distribution subindustry, Paragon Care's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paragon Care Altman Z-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Paragon Care's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Paragon Care's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Paragon Care's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
-0.0113
+
1.4
*
-0.0128
+
3.3
*
0.0446
+
0.6
*
0.2445
+
1.0
*
2.9057
=
3.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Paragon Care (ASX:PGC) has a Altman Z-Score of 3.17 as of Jul. 01, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Paragon Care and its competitors. This is 74% above median its historical median of 1.82. According to the industry distribution chart, Paragon Care ranks #39 out of 117 companies in the Medical Distribution industry, placing it in the top 33.3%.
Is Paragon Care's Altman Z-Score too high?
Paragon Care's current Altman Z-Score of 3.17 is 74% above median its 10-year median of 1.82. The Medical Distribution industry median Altman Z-Score is 2.49. Paragon Care's value of 3.17 is 27.3% above this industry median. Based on the distribution chart, Paragon Care ranks #39 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Paragon Care has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Paragon Care's Altman Z-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Paragon Care ranks #39 out of 117 companies for Altman Z-Score. This puts Paragon Care in the upper half of its industry. The industry median Altman Z-Score is 2.49. Paragon Care's value of 3.17 is 27.3% above this benchmark. While the company's 10-year median is 1.82 vs. the industry median of 2.49, Paragon Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Distribution company?
The median Altman Z-Score among Medical Distribution companies is 2.49, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paragon Care's current Altman Z-Score of 3.17 is 27.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Paragon Care and its competitors. For the Medical Distribution industry, the median Altman Z-Score is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paragon Care's current Altman Z-Score is 3.17, which is 74% above median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paragon Care stock overvalued right now?
Based on GuruFocus' analysis, Paragon Care (ASX:PGC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.17 — trading 58.8% below its estimated fair value. The current Altman Z-Score is 3.17, which is 74% above median its 10-year median of 1.82 and 27.3% above the Medical Distribution industry median of 2.49. Paragon Care's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Paragon Care (ASX:PGC), the current Altman Z-Score is 3.17 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paragon Care (ASX:PGC) Overvalued in 2026?
Based on GuruFocus' analysis, Paragon Care stock appears to be undervalued.
The current stock price of A$0.17 is trading 58.8% below its estimated GF Value™ of A$0.40.
GuruFocus considers Paragon Care to be Possible Value Trap.
Key valuation signals for ASX:PGC:
Altman Z-Score: 3.17 (74% above median its 10-year median of 1.82)
GF Value™: A$0.40 vs. price of A$0.17 (58.8% below fair value)
Industry Position: 27.3% above the Medical Distribution median (#39 of 117)
No single metric tells the full story. See the ASX:PGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paragon Care Ltd is a medical device company. The company provides medical equipment, devices, and consumables medical products to the healthcare market. The company provides solutions to various healthcare markets, aged care, and veterinary markets. The group is organized into two operating segments: ParagonCare and CH2 Holdings and the majority of its revenues are generated from the CH2 Holdings segment engaged in the distribution of pharmaceuticals, medical consumables, nutritional, and over-the-counter products to the healthcare market.
56GF Score
Get the complete analysis for ASX:PGC
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PGC has been successfully added to your 
